High Prevalence of Bronchiectasis in Emphysema-predominant COPD Patients

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2018 Jul 11

PMID 29988718

Citations 13

Authors

Shuang Dou

Chunyan Zheng

Liwei Cui

Mengshuang Xie

Wei Wang

Hui Tian

Kang Li

Kaidi Liu

Xinyu Tian

Xin Wang

Qun Zhang

Xin Ai

Junchao Che

Qixiao Liu

Haijun Li

Wei Xiao

Affiliations

Soon will be listed here.

Abstract

Background: COPD has been identified as an etiology or related disease of bronchiectasis, and bronchiectasis has been classified as a comorbidity of COPD. In this study, we investigated the prevalence of bronchiectasis in different phenotypes of COPD subjects and the correlation between bronchiectasis and different phenotypes, especially emphysema.

Methods: COPD patients were recruited from April 2012 to December 2015. The presence of bronchiectasis and related information were statistically analyzed. COPD subjects were separated into subgroups in two ways: COPD with and without bronchiectasis groups and emphysema-predominant (emphysema index, EI≥9.9%) and non-emphysema-predominant (EI<9.9%) groups.

Results: In total, 1,739 COPD patients were incorporated into the study, among which 140 cases (8.1%) were accompanied with radiological bronchiectasis. COPD patients with concomitant bronchiectasis presented worse pulmonary function (FEV% predicted, <0.001), higher EI (15.0% vs 13.4%, <0.001), and higher proportion of pulmonary hypertension and cor pulmonale (6.4% vs 2.4%, =0.005 and 23.6% vs 16.1%, =0.022) than patients without bronchiectasis. Of all the COPD patients, 787 with EI data were divided into emphysema-predominant (n=369) and non-emphysema-predominant groups (n=418). The proportion of bronchiectasis was 16.5% and 10.3% (=0.01), respectively. Severity of bronchiectasis increased as the degree of airflow limitation (=-0.371, <0.001) and emphysema increased (=0.226, =0.021). After adjusting confounding factors, FEV% predicted (OR, 1.636; 95% CI, 1.219-2.197; =0.001) and EI (OR, 1.993; 95% CI, 1.199-3.313; =0.008) were significantly related with the presence of bronchiectasis in COPD patients.

Conclusion: The proportion of bronchiectasis is higher in emphysema-predominant COPD subjects. Emphysema measured by EI and FEV% predicted are independent predictors for bronchiectasis in COPD subjects, while the underlying mechanism deserves further investigation.

Citing Articles

Incidental Findings in Lung Cancer Screening.

Lin Y, Khurelsukh K, Li I, Wu C, Wu Y, Lin G Cancers (Basel). 2024; 16(14).

PMID: 39061238 PMC: 11274500. DOI: 10.3390/cancers16142600.

The COPD Foundation on Its Twentieth Anniversary.

Malanga E, Thomashow B, Wright J, Walsh L, Carlomagno C, Sullivan J Chronic Obstr Pulm Dis. 2024; 11(3):247-260.

PMID: 38809791 PMC: 11216227. DOI: 10.15326/jcopdf.2024.0527.

The role of Neutrophil counts, infections and Smoking in mediating the Effect of Bronchiectasis on Chronic Obstructive Pulmonary Disease: a mendelian randomization study.

Gu L, Liu W, Huang J, Zhu L, Hu X, Yue J BMC Pulm Med. 2024; 24(1):144.

PMID: 38509541 PMC: 10953251. DOI: 10.1186/s12890-024-02962-6.

Comorbidities in COPD: Current and Future Treatment Challenges.

Mariniello D, DAgnano V, Cennamo D, Conte S, Quarcio G, Notizia L J Clin Med. 2024; 13(3).

PMID: 38337438 PMC: 10856710. DOI: 10.3390/jcm13030743.

Early Diagnosis of High-Risk Chronic Obstructive Pulmonary Disease Based on Quantitative High-Resolution Computed Tomography Measurements.

Zhang W, Zhao Y, Tian Y, Liang X, Piao C Int J Chron Obstruct Pulmon Dis. 2024; 18:3099-3114.

PMID: 38162987 PMC: 10757779. DOI: 10.2147/COPD.S436803.

References

Pasteur M, Bilton D, Hill A . British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010; 65(7):577. DOI: 10.1136/thx.2010.142778. View

Bhalla M, Turcios N, Aponte V, Jenkins M, Leitman B, McCauley D . Cystic fibrosis: scoring system with thin-section CT. Radiology. 1991; 179(3):783-8. DOI: 10.1148/radiology.179.3.2027992. View

Martinez-Garcia M, Soler-Cataluna J, Donat Sanz Y, Catalan Serra P, Agramunt Lerma M, Ballestin Vicente J . Factors associated with bronchiectasis in patients with COPD. Chest. 2011; 140(5):1130-1137. DOI: 10.1378/chest.10-1758. View

Gatheral T, Kumar N, Sansom B, Lai D, Nair A, Vlahos I . COPD-related bronchiectasis; independent impact on disease course and outcomes. COPD. 2014; 11(6):605-14. DOI: 10.3109/15412555.2014.922174. View

Shaykhiev R, Crystal R . Early events in the pathogenesis of chronic obstructive pulmonary disease. Smoking-induced reprogramming of airway epithelial basal progenitor cells. Ann Am Thorac Soc. 2014; 11 Suppl 5:S252-8. PMC: 4298974. DOI: 10.1513/AnnalsATS.201402-049AW. View

Ni Y, Shi G, Yu Y, Hao J, Chen T, Song H . Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systemic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015; 10:1465-75. PMC: 4524532. DOI: 10.2147/COPD.S83910. View

Martinez-Garcia M, de la Rosa Carrillo D, Soler-Cataluna J, Donat-Sanz Y, Catalan Serra P, Lerma M . Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 187(8):823-31. DOI: 10.1164/rccm.201208-1518OC. View

Stoller J, Aboussouan L . A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med. 2011; 185(3):246-59. DOI: 10.1164/rccm.201108-1428CI. View

Xie M, Wang W, Dou S, Cui L, Xiao W . Quantitative computed tomography measurements of emphysema for diagnosing asthma-chronic obstructive pulmonary disease overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2016; 11:953-61. PMC: 4866743. DOI: 10.2147/COPD.S104484. View

10.

Parr D, Guest P, Reynolds J, Dowson L, Stockley R . Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2007; 176(12):1215-21. DOI: 10.1164/rccm.200703-489OC. View

11.

Du Q, Jin J, Liu X, Sun Y . Bronchiectasis as a Comorbidity of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(3):e0150532. PMC: 4792534. DOI: 10.1371/journal.pone.0150532. View

12.

Chan E, Iseman M . Significance of bronchiectasis in patients with alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2008; 178(2):208. DOI: 10.1164/ajrccm.178.2.208. View

13.

Crystal R . Airway basal cells. The "smoking gun" of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014; 190(12):1355-62. PMC: 4299651. DOI: 10.1164/rccm.201408-1492PP. View

14.

Russell D, Gaggar A, Solomon G . Neutrophil Fates in Bronchiectasis and Alpha-1 Antitrypsin Deficiency. Ann Am Thorac Soc. 2016; 13 Suppl 2:S123-9. PMC: 5015725. DOI: 10.1513/AnnalsATS.201512-805KV. View

15.

Hogg J . Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004; 364(9435):709-21. DOI: 10.1016/S0140-6736(04)16900-6. View

16.

Agusti A, Calverley P, Celli B, Coxson H, Edwards L, Lomas D . Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010; 11:122. PMC: 2944278. DOI: 10.1186/1465-9921-11-122. View

17.

Cui L, Ji X, Xie M, Dou S, Wang W, Xiao W . Role of inspiratory capacity on dyspnea evaluation in COPD with or without emphysematous lesions: a pilot study. Int J Chron Obstruct Pulmon Dis. 2017; 12:2823-2830. PMC: 5628691. DOI: 10.2147/COPD.S142016. View

18.

Jin J, Yu W, Li S, Lu L, Liu X, Sun Y . Factors associated with bronchiectasis in patients with moderate-severe chronic obstructive pulmonary disease. Medicine (Baltimore). 2016; 95(29):e4219. PMC: 5265763. DOI: 10.1097/MD.0000000000004219. View

19.

McDonough J, Yuan R, Suzuki M, Seyednejad N, Elliott W, Sanchez P . Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011; 365(17):1567-75. PMC: 3238466. DOI: 10.1056/NEJMoa1106955. View

20.

Blasi F, Chalmers J, Aliberti S . COPD and bronchiectasis: phenotype, endotype or co-morbidity?. COPD. 2014; 11(6):603-4. DOI: 10.3109/15412555.2014.974744. View